Prospective, intensive study of metabolic changes associated with 48 weeks of amprenavir-based antiretroviral therapy

Clinical Infectious Diseases

Volumn 35, Issue 4, 2002, Pages 475-481

  Dubé, Michael P ^a   Qian, Dajun ^b   Edmondson Melançon, Hannah ^c   Sattler, Fred R ^c   Goodwin, Diane ^e   Martinez, Carmen ^d   Williams, Vanessa ^e   Johnson, Debra ^c   Buchanan, Thomas A ^d  

^a INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Department of Preventive Medicine ^*  (United States)

^c Department of Medicine   (United States)

^d UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^e GLAXOSMITHKLINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR; AMPRENAVIR; ANTIRETROVIRUS AGENT; CHOLESTEROL; DIDANOSINE; GLUCOSE; HIGH DENSITY LIPOPROTEIN; INSULIN; LAMIVUDINE; LOW DENSITY LIPOPROTEIN; STAVUDINE; TRIACYLGLYCEROL;

ADULT; ARTICLE; BODY FAT; BONE MINERAL; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; CLINICAL TRIAL; DRUG HYPERSENSITIVITY; FEMALE; GLUCOSE BLOOD LEVEL; GLUCOSE TOLERANCE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INSULIN BLOOD LEVEL; INSULIN RESISTANCE; INSULIN SENSITIVITY; LIPOPROTEIN BLOOD LEVEL; MALE; METABOLISM; PRIORITY JOURNAL; TRIACYLGLYCEROL BLOOD LEVEL; WEIGHT GAIN;

ADULT; ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; BODY COMPOSITION; CARBAMATES; DRUG ADMINISTRATION SCHEDULE; FEMALE; GLUCOSE; HIV INFECTIONS; HUMANS; LIPID METABOLISM; MALE; PILOT PROJECTS; PROSPECTIVE STUDIES; SULFONAMIDES;

EID: 0037103097     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/341489     Document Type: Article

References (31)

1. Protease inhibitor-associated hyperglycaemia
2. Severe diabetes associated with protease inhibitor therapy
3. Insulin resistance in HIV protease inhibitor-associated diabetes
4. Treatment with protease inhibitors associated with peripheral insulin resistance and impaired oral glucose tolerance in HIV-1-infected patients
5. A syndrome of peripheral lipodystrophy, hyperlipidaemia, and insulin resistance due to HIV protease inhibitors
6. Prospective evaluation of the effect of initiating indinavir-based therapy on insulin sensitivity and B-cell function in HIV-infected patients
7. Hyperlipidemia and insulin resistance are induced by protease inhibitors independent of changes in body composition in patients with HIV infection
8. Metabolic effects of indinavir in healthy HIV-seronegative men
9. Dietary fat alters HIV protease inhibitor-induced metabolic changes in mice
10. HIV protease inhibitors block adipogenesis and increase lipolysis in vitro
11. Preliminary guidelines for the evaluation and management of dyslipidemia in adults infected with human immunodeficiency virus and receiving antiretroviral therapy: Recommendations of the Adult AIDS Clinical Trials Group Cardiovascular Disease Focus Group
12. Disorders of glucose metabolism in patients infected with human immunodeficiency virus
13. Metabolic abnormalities and cardiovascular disease risk factors in adults with human immunodeficiency virus infection and lipodystrophy
14. Increased PAI-1 and tPA antigen levels are reduced with metformin therapy in HIV-infected patients with fat redistribution and insulin resistance
15. Repeatability of insulin sensitivity and glucose effectiveness from the minimal model
16. Measurement of lipoprotein subclass profiles by nuclear magnetic resonance spectroscopy
17. Physiologic evaluation of factors controlling glucose tolerance in man
18. Homeostasis model assessment: Insulin resistance and B-cell function from fasting plasma glucose and insulin concentrations in man
19. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge
20. Screening for type 2 diabetes
21. Indinavir acutely inhibits insulin-stimulated glucose disposal in humans: A randomized, placebo-controlled study
22. Association of severe insulin resistance with both loss of limb fat and elevated serum tumor necrosis factor receptor levels in HIV lipodystrophy
23. Fat distribution evaluated by computed tomography and metabolic abnormalities in patients undergoing antiretroviral therapy: Preliminary results of the LIPOCO study
24. Risk of lipodystrophy in HIV-1-infected patients treated with protease inhibitors: A prospective cohort study
25. Effect on ritonavir on lipids and post-heparin lipase activities in normal subjects
26. Association of small low-density lipoprotein particles with the incidence of coronary artery disease in men and women
27. Atherogenic dyslipidemia in HIV-infected individuals treated with protease inhibitors. Swiss HIV Cohort Study
28. HIV-1 protease inhibitors induce an increase of triglyceride level in HIV-infected men without modification of insulin sensitivity a longitudinal study
29. Nevirapine-containing antiretroviral therapy in HIV-1 infected patients results in an antiatherogenic lipid profile
30. Pathogenesis of HIV-1-protease inhibitor-associated peripheral lipodystrophy, hyperlipidaemia, and insulin resistance